;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Allob: Phase IIa started

    Bone Therapeutics S.A., Gosselies, Belgium Product: Allob Business: Musculoskeletal Molecular target: NA Description: Allogeneic osteoblastic cell therapy Indication: Promote lumbar spine fusion Endpoint: Lumbar fusion …

    Published on 9/29/2014
  • Bertilimumab: Phase II started

    iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), Tarrytown, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab (iCo-008, CAT-…

    Published on 9/29/2014
  • Cysteamine: Phase IIa started

    NovaBiotics Ltd., Aberdeen, U.K. Product: Cysteamine (oral Lynovex) (NM001) Business: Pulmonary Molecular target: NA Description: Oral dual mucoactive-antibacterial Indication: Treat cystic fibrosis (CF) Endpoint: …

    Published on 9/29/2014
  • Flexion Therapeutics pipeline update

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Business: Autoimmune Flexion said FDA placed a clinical hold on a Phase IIb trial of FX006 to treat osteoarthritis (OA) of the knee following an infection in 1 …

    Published on 9/29/2014
  • Fosbretabulin: Phase II started

    OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif. Product: Fosbretabulin (Combretastatin A4P, Zybrestat)) Business: Cancer Molecular target: Tubulin Description: A4 prodrug phosphatase-activated tumor vascular …

    Published on 9/29/2014
  • HaMPCs: Phase 0 started

    Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Product: HaMPCs, ReJoin Business: Musculoskeletal Molecular target: NA Description: Autologous human adipose tissue-derived mesenchymal precursor cells …

    Published on 9/29/2014
  • K-134: Phase II ongoing

    D. Western Therapeutics Institute Inc. (JASDAQ:4576), Nagoyashi, Japan Kowa Co. Ltd., Nagoya, Japan Product: K-134 Business: Cardiovascular Molecular target: Phosphodiesterase-3 (PDE-3) Description: Phosphodiesterase-3…

    Published on 9/29/2014
  • Lyxumia lixisenatide: Postmarketing study started

    Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lyxumia lixisenatide (AVE0010, ZP10) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 …

    Published on 9/29/2014
  • MGN1703: Phase III started

    Mologen AG (Xetra:MGN), Berlin, Germany Product: MGN1703 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) …

    Published on 9/29/2014
  • PEGPH20: Phase Ib/II ongoing

    Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Product: PEGPH20 (formerly PEGrHuPH20) Business: Cancer Molecular target: Hyaluronan Description: Recombinant human PH20 hyaluronidase enzyme conjugated to …

    Published on 9/29/2014
  • Rivipansel: Phase III delayed

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Rivipansel (GMI-1070, PF-06460031) Business: Hematology Molecular target: E selectin (SELE) (CD62E); P selectin (SELP)…

    Published on 9/29/2014
  • RSV-F vaccine: Phase II started

    Novavax Inc. (NASDAQ:NVAX), Rockville, Md. Product: RSV-F vaccine Business: Infectious Molecular target: NA Description: Respiratory syncytial virus (RSV) vaccine directed against the viral fusion F protein and …

    Published on 9/29/2014
  • TH-302: Phase III ongoing

    Threshold Pharmaceuticals Inc. (NASDAQ:THLD), South San Francisco, Calif. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: TH-302 Business: Cancer Molecular target: Not available Description: Hypoxia-activated …

    Published on 9/29/2014
  • TRC105: Phase IIa started

    Tracon Pharmaceuticals Inc., San Diego, Calif. Product: TRC105 Business: Cancer Molecular target: Endoglin (CD105) (ENG) Description: Human chimeric mAb against endoglin (CD105; ENG) Indication: Treat advanced soft …

    Published on 9/29/2014
  • ALKS 3831: Completed Phase II enrollment

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 3831 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Combination of samidorphan, a mu opioid receptor (OPRM1; MOR) antagonist…

    Published on 9/22/2014
  • ALX-0962: Development discontinued

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Product: ALX-0962 Business: Inflammation Molecular target: Immunoglobulin E (IgE) Description: Anti-IgE monovalent Nanobody Indication: Treat severe allergic asthma Endpoint: …

    Published on 9/22/2014
  • Anagrelide CR: Phase II started

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: Anagrelide CR (GALE-401) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide Indication: Treat …

    Published on 9/22/2014
  • ARRY-543: Clinical trial started

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Aslan Pharmaceuticals Pte. Ltd., Singapore Product: ARRY-543, ASLAN001 Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR); Epidermal growth …

    Published on 9/22/2014
  • BGB-3111: Phase I started

    BeiGene Co. Ltd., Beijing, China Product: BGB-3111 Business: Cancer Molecular target: Bruton's tyrosine kinase (Btk) Description: Highly selective oral Bruton's tyrosine kinase (Btk) inhibitor Indication: Treat cancer …

    Published on 9/22/2014
  • Biosimilar insulin glargine: Phase III started

    Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Product: Biosimilar insulin glargine (Basalog) Business: Endocrine/Metabolic Molecular target: NA Description: Biosimilar …

    Published on 9/22/2014
  • Biosimilar insulin glargine: Phase III started

    Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Product: Biosimilar insulin glargine (Basalog) Business: Endocrine/Metabolic Molecular target: NA Description: Biosimilar …

    Published on 9/22/2014
  • C-Cure: Phase III ongoing

    Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Product: C-Cure (C3BS-CQR-1) Business: Cardiovascular Molecular target: NA Description: Cellular therapy based on autologous stem cells …

    Published on 9/22/2014
  • CTP-730: Phase I started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: CTP-730 Business: Inflammation Molecular target: NA Description: Deuterium-substituted compound Indication:…

    Published on 9/22/2014
  • Custirsen sodium: Completed Phase III enrollment

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Custirsen sodium (TV-…

    Published on 9/22/2014
  • FX006: Phase II hold

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Product: FX006 Business: Autoimmune Molecular target: NA Description: Sustained-release intra-articular formulation of triamcinolone acetonide Indication: Treat…

    Published on 9/22/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993